MPS NEW

Clinical Cancer Drugs

Aims and Scope:

Clinical Cancer Drugs publishes original research, expert reviews, and thematic issues covering all core areas of translational and clinical cancer drug research.

The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading to clinical oncologists, toxicologists, medicinal chemists, and pharmacologists.

Clinical Cancer Drugs is an international, peer-reviewed journal on all aspects of cancer drugs published continuously (print & online) by Bentham Science Publishers.

Editor-in-Chief:

Giulio FranciaDepartment of Biological Sciences
The University of Texas
El Paso, TX
United States of America

ISSN: 2212-697X (Print)

eISSN: 2212-6988 (Online)

Special Issues With Active Call for Papers

Submission closes on: May 28, 2027

Translational Advances in Cancer Therapeutics: Natural Product-Derived Anticancer Agents, Engineered Cellular Immunotherapies, and Clinical Perspectives

Current cancer treatment is rapidly shifting from traditional cytotoxic therapies to those based on mechanisms, precision targeting, and immune system activation. This special issue, "Translational Advances in Cancer Therapeutics: Natural Product-Derived Anticancer Agents, Engineered Cellular Immunotherapies, and Clinical Perspectives", is dedicated to delivering high-quality reviews and research on promising anticancer approaches with practical and clinical relevance. It will delve into natural product-derived agents, phytochemicals, and bioactive compounds, highlighting their roles in cancer prevention, induction of... see more

Guest Editor(s): Dr. Ajay Kumar
Co-Guest Editor(s): Dr. Paresh Vishwasrao

Start Submission

Submission closes on: Oct 02, 2026

AI in Precision Oncology and Psycho-Oncology

The scope of this project encompasses several cutting-edge areas at the intersection of artificial intelligence and oncology. First, it involves developing AI models for drug response prediction and biomarker discovery, enabling more accurate and personalized treatment strategies. Second, it focuses on predictive models for mental health outcomes in cancer patients, addressing critical psychological challenges. Third, AI-based interventions will be explored for managing anxiety, depression, and stress, common but often overlooked in oncology. Finally, the project... see more

Guest Editor(s): Dr. Kadir Uludag
Co-Guest Editor(s): Dr. Yanhua Bi

Start Submission

Submission closes on: Aug 02, 2026

Disrupting the Warburg Effect: Enzymatic Inhibition Strategies in Tumor Glycolysis

The Warburg Effect, a hallmark of cancer metabolism, describes the preference of tumor cells for aerobic glycolysis, enabling rapid energy production and biosynthesis to fuel uncontrolled proliferation. This metabolic reprogramming is orchestrated by key glycolytic enzymes such as hexokinase, phosphoglucose isomerase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase, pyruvate kinase, and lactate dehydrogenase. Targeting these enzymes offers a promising therapeutic avenue to starve cancer cells and sensitise them to existing treatments.... see more

Guest Editor(s): Dr. Dolly Sharma
Co-Guest Editor(s): Dr. Bhaswati Banerjee,Dr. Shalini Mani,Dr. Samiksha Wasnik

Start Submission